fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Salbutamol

Form:

20 of 20 products shown

7 general benefit · 5 Limited Use · 8 not a benefit

PMS-Salbutamol · DIN 02208229 · 1 mg/mL · Inh Sol- 2.5mL Pk

Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 265 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 266 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 267 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 268 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Salbutamol · DIN 02208229 Manufacturer: Pharmascience Inc.; listing date 1997-04-10 Health Canada: Marketed since 2010-05-07 · brand PMS-SALBUTAMOL · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 1 MG/ML · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Salbutamol: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3617). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02208229)

Source record
DIN 02208229: PMS-Salbutamol Raw flags: sec12=Y, sec3=Y Item: 121200048; group id 232; item number 0412; lccId 00040; manufacturer id PMS Source form: Inh Sol- 2.5mL Pk; strength: 1mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.3617; ministry $0.3617 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02208229 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19763
Interchangeable products
Teva-Salbutamol Sterinebs P.F. · DIN 01926934 · $0.3617 Ventolin Nebules P.F. · DIN 02213419 · not recorded
Shortage status: resolved shortage (ended March 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02208229
Shortage record checked October 6, 2026

Teva-Salbutamol Sterinebs P.F. · DIN 01926934 · 1 mg/mL · Inh Sol- 2.5mL Pk

Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 265 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 266 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 267 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 268 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Salbutamol Sterinebs P.F. · DIN 01926934 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2012-07-06 · brand TEVA-SALBUTAMOL STERINEBS P.F. · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 1 MG/ML · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Salbutamol Sterinebs P.F.: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3617). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01926934)

Source record
DIN 01926934: Teva-Salbutamol Sterinebs P.F. Raw flags: sec12=Y, sec3=Y Item: 121200048; group id 232; item number 0412; lccId 00040; manufacturer id TEV Source form: Inh Sol- 2.5mL Pk; strength: 1mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.3617; ministry $0.3617 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926934 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13550
Interchangeable products
PMS-Salbutamol · DIN 02208229 · $0.3617 Ventolin Nebules P.F. · DIN 02213419 · not recorded
Shortage status: resolved shortage (ended November 5, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926934
Shortage record checked October 6, 2026

PMS-Salbutamol · DIN 02208237 · 2 mg/mL · Inh Sol- 2.5mL Pk

Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 265 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 266 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 267 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 268 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Salbutamol · DIN 02208237 Manufacturer: Pharmascience Inc.; listing date 1997-04-10 Health Canada: Marketed since 2010-05-07 · brand PMS-SALBUTAMOL · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2 MG/ML · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Salbutamol: Formulary list price $0.68 per unit (the source does not state the unit; exact figure $0.6750). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02208237)

Source record
DIN 02208237: PMS-Salbutamol Raw flags: sec12=Y, sec3=Y Item: 121200070; group id 233; item number 0413; lccId 00041; manufacturer id PMS Source form: Inh Sol- 2.5mL Pk; strength: 2mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6750; ministry $0.6750 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02208237 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19762
Interchangeable products
Teva-Salbutamol Sterinebs P.F. · DIN 02173360 · $0.6750 Ventolin Nebules P.F. · DIN 02213427 · not recorded
Shortage status: resolved shortage (ended November 30, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02208237
Shortage record checked October 6, 2026

Teva-Salbutamol Sterinebs P.F. · DIN 02173360 · 2 mg/mL · Inh Sol- 2.5mL Pk

Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 265 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 266 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 267 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 268 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Salbutamol Sterinebs P.F. · DIN 02173360 Manufacturer: Teva Canada Limited; listing date 1997-04-10 Health Canada: Marketed since 2012-07-05 · brand TEVA-SALBUTAMOL STERINEBS P.F. · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2 MG/ML · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02173360)

Source record
DIN 02173360: Teva-Salbutamol Sterinebs P.F. Raw flags: sec12=Y, sec3=Y Item: 121200070; group id 233; item number 0413; lccId 00041; manufacturer id TEV Source form: Inh Sol- 2.5mL Pk; strength: 2mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6871; ministry $0.6750 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02173360 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19058
Interchangeable products
PMS-Salbutamol · DIN 02208237 · $0.6750 Ventolin Nebules P.F. · DIN 02213427 · not recorded
Shortage status: resolved shortage (ended June 20, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02173360
Shortage record checked October 6, 2026

Ventolin · DIN 02213486 · 5 mg/mL · Inh Sol-10mL Pk

Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 256 Patients who have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 257 Patients with cystic fibrosis in whom nebulizer therapy is indicated; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 258 Patients with severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 259 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Ventolin · DIN 02213486 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1998-04-03 Health Canada: Marketed since 2002-08-26 · brand VENTOLIN RESPIRATOR SOLUTION · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 5 MG/ML · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ventolin: Formulary list price $3.17 per unit (the source does not state the unit; exact figure $3.1700). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02213486)

Source record
DIN 02213486: Ventolin Raw flags: sec12=Y, sec3=Y Item: 121200025; group id 234; item number 0414; lccId 00042; manufacturer id GSK Source form: Inh Sol-10mL Pk; strength: 5mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.1700; ministry $3.1700 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02213486 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43108
Shortage status: resolved shortage (ended October 30, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02213486
Shortage record checked October 6, 2026

Apo-Salbutamol HFA · DIN 02245669 · 100 mcg/Metered Dose · inhaler, 200 doses

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Salbutamol HFA · DIN 02245669 Manufacturer: Apotex Inc.; listing date 2003-01-01 Health Canada: Marketed since 2019-12-16 · brand APO-SALBUTAMOL HFA · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Salbutamol HFA: Formulary list price $5.00 per unit (the source does not state the unit; exact figure $5.0000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245669)

Source record
DIN 02245669: Apo-Salbutamol HFA Raw flags: sec3=Y Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id APX Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose Recorded listing: General benefit Source prices (unrounded): $5.0000; ministry $5.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245669 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69769
Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000 Apo-Salvent · DIN 00790419 · not recorded Novo-Salmol · DIN 00874086 · not recorded Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded Salbutamol HFA · DIN 02419858 · $5.0000 Teva-Salbutamol HFA · DIN 02326450 · $5.0000 Ventolin · DIN 02213478 · not recorded Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: active shortage (reported June 16, 2026, last updated June 18, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245669
Shortage record checked October 6, 2026

Salbutamol HFA · DIN 02419858 · 100 mcg/Metered Dose · inhaler, 200 doses

General benefitMarketed · checked November 19, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Salbutamol HFA · DIN 02419858 Manufacturer: Sanis Health Inc.; listing date 2020-04-07 Health Canada: Marketed since 2014-02-13 · brand SALBUTAMOL HFA · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Salbutamol HFA: Formulary list price $5.00 per unit (the source does not state the unit; exact figure $5.0000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02419858)

Source record
DIN 02419858: Salbutamol HFA Raw flags: sec3=Y Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id SAI Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose Recorded listing: General benefit Source prices (unrounded): $5.0000; ministry $5.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02419858 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90447
Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000 Apo-Salbutamol HFA · DIN 02245669 · $5.0000 Apo-Salvent · DIN 00790419 · not recorded Novo-Salmol · DIN 00874086 · not recorded Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded Teva-Salbutamol HFA · DIN 02326450 · $5.0000 Ventolin · DIN 02213478 · not recorded Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: resolved shortage (ended March 31, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02419858
Shortage record checked October 6, 2026

Teva-Salbutamol HFA · DIN 02326450 · 100 mcg/Metered Dose · inhaler, 200 doses

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Salbutamol HFA · DIN 02326450 Manufacturer: Teva Canada Limited; listing date 2011-05-19 Health Canada: Marketed since 2018-03-21 · brand TEVA-SALBUTAMOL HFA · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Salbutamol HFA: Formulary list price $5.00 per unit (the source does not state the unit; exact figure $5.0000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02326450)

Source record
DIN 02326450: Teva-Salbutamol HFA Raw flags: sec3=Y Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id TEV Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose Recorded listing: General benefit Source prices (unrounded): $5.0000; ministry $5.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02326450 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81180
Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000 Apo-Salbutamol HFA · DIN 02245669 · $5.0000 Apo-Salvent · DIN 00790419 · not recorded Novo-Salmol · DIN 00874086 · not recorded Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded Salbutamol HFA · DIN 02419858 · $5.0000 Ventolin · DIN 02213478 · not recorded Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: resolved shortage (ended March 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02326450
Shortage record checked October 6, 2026

Ventolin HFA · DIN 02241497 · 100 mcg/Metered Dose · inhaler, 200 doses

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ventolin HFA · DIN 02241497 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2009-11-13 Health Canada: Marketed since 2001-11-22 · brand VENTOLIN HFA · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02241497)

Source record
DIN 02241497: Ventolin HFA Raw flags: sec3=Y Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id GSK Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose Recorded listing: General benefit Source prices (unrounded): $6.0000; ministry $5.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02241497 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65137
Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000 Apo-Salbutamol HFA · DIN 02245669 · $5.0000 Apo-Salvent · DIN 00790419 · not recorded Novo-Salmol · DIN 00874086 · not recorded Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded Salbutamol HFA · DIN 02419858 · $5.0000 Teva-Salbutamol HFA · DIN 02326450 · $5.0000 Ventolin · DIN 02213478 · not recorded
Shortage status: resolved shortage (ended April 24, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241497
Shortage record checked October 6, 2026

Airomir HFA · DIN 02232570 · 100 mcg/Metered Dose · inhaler, 200 doses

General benefitDormant since July 30, 2025 · checked October 5, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Airomir HFA · DIN 02232570 Manufacturer: Graceway Pharmaceuticals; listing date 1998-12-31 Health Canada: Dormant since 2025-07-30 · brand AIROMIR · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02232570)

Source record
DIN 02232570: Airomir HFA Raw flags: sec3=Y Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id GRA Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose Recorded listing: General benefit Source prices (unrounded): $6.2593; ministry $5.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02232570 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52048
Interchangeable products
Apo-Salbutamol HFA · DIN 02245669 · $5.0000 Apo-Salvent · DIN 00790419 · not recorded Novo-Salmol · DIN 00874086 · not recorded Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded Salbutamol HFA · DIN 02419858 · $5.0000 Teva-Salbutamol HFA · DIN 02326450 · $5.0000 Ventolin · DIN 02213478 · not recorded Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: discontinued (January 4, 2023, reported by BAUSCH HEALTH, CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02232570
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 30, 2025 — choose a marketed DIN from the same-category list.

Ventolin · PIN 01961039 · 2 mg · tablet

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
1 brand, same coverage
Ventolin · DIN 01961039 Manufacturer: Glaxo Canada Inc.; listing date 1996-10-01 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Ventolin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 01961039)

Source record
DIN 01961039: Ventolin Raw flags: notABenefit=Y, sec3=Y Item: 121200013; group id 235; item number 0416; lccId None; manufacturer id GLA Source form: Tab; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01961039 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Apo-Salvent · DIN 02146843 · $0.1274
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01961039
Shortage record checked October 6, 2026

Apo-Salvent · DIN 02146843 · 2 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2018-12-20 — choose a marketed DIN from the same-category list.Discontinued December 20, 2018 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-12-20 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-12-20 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Salvent · DIN 02146843 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2018-12-20 · brand APO-SALVENT TABLETS - 2MG · ATC R03CC02 SALBUTAMOL · form Tablet · route Oral · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Salvent: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1274). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02146843)

Source record
DIN 02146843: Apo-Salvent Raw flags: sec3=Y Item: 121200013; group id 235; item number 0416; lccId None; manufacturer id APX Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.1274; ministry $0.1274 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02146843 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18068
Interchangeable products
Ventolin · DIN 01961039 · not recorded
Shortage status: discontinued (July 12, 2018, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02146843
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since December 20, 2018 — choose a marketed DIN from the same-category list.

Apo-Salvent · DIN 02146851 · 4 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2018-07-12 — choose a marketed DIN from the same-category list.Discontinued July 12, 2018 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-07-12 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-07-12 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Salvent · DIN 02146851 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2018-07-12 · brand APO-SALVENT TABLETS - 4MG · ATC R03CC02 SALBUTAMOL · form Tablet · route Oral · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 4 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Salvent: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2134). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02146851)

Source record
DIN 02146851: Apo-Salvent Raw flags: sec3=Y Item: 121200021; group id 235; item number 0417; lccId None; manufacturer id APX Source form: Tab; strength: 4mg Recorded listing: General benefit Source prices (unrounded): $0.2134; ministry $0.2134 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02146851 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18067
Interchangeable products
Ventolin · DIN 01932691 · not recorded
Shortage status: discontinued (July 12, 2018, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02146851
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 12, 2018 — choose a marketed DIN from the same-category list.

Ventolin Nebules P.F. · DIN 02213419 · 1 mg/mL · Inh Sol- 2.5mL Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.Discontinued July 5, 2022 · checked November 19, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 265 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 266 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 267 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 268 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Ventolin Nebules P.F. · DIN 02213419 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1998-10-21 Health Canada: Cancelled post market since 2022-07-05 · brand VENTOLIN NEBULES P.F. - 2.5MG/2.5ML · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ventolin Nebules P.F.: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02213419)

Source record
DIN 02213419: Ventolin Nebules P.F. Raw flags: notABenefit=Y, sec3=Y Item: 121200048; group id 232; item number 0412; lccId 00040; manufacturer id GSK Source form: Inh Sol- 2.5mL Pk; strength: 1mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02213419 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43100
Interchangeable products
PMS-Salbutamol · DIN 02208229 · $0.3617 Teva-Salbutamol Sterinebs P.F. · DIN 01926934 · $0.3617
Shortage status: discontinued (June 17, 2022, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02213419
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 5, 2022 — choose a marketed DIN from the same-category list.

Ventolin Nebules P.F. · DIN 02213427 · 2 mg/mL · Inh Sol- 2.5mL Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.Discontinued July 5, 2022 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 265 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 266 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 267 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 268 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ventolin Nebules P.F. · DIN 02213427 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2006-06-15 Health Canada: Cancelled post market since 2022-07-05 · brand VENTOLIN NEBULES P.F. - 5MG/2.5ML · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 5 MG/2.5ML · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ventolin Nebules P.F.: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02213427)

Source record
DIN 02213427: Ventolin Nebules P.F. Raw flags: notABenefit=Y, sec3=Y Item: 121200070; group id 233; item number 0413; lccId 00041; manufacturer id GSK Source form: Inh Sol- 2.5mL Pk; strength: 2mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02213427 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43101
Interchangeable products
PMS-Salbutamol · DIN 02208237 · $0.6750 Teva-Salbutamol Sterinebs P.F. · DIN 02173360 · $0.6750
Shortage status: discontinued (June 29, 2022, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02213427
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 5, 2022 — choose a marketed DIN from the same-category list.

Ventolin · DIN 01932691 · 4 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.Discontinued September 10, 1996 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Ventolin · DIN 01932691 Manufacturer: Glaxo Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 1996-09-10 · brand VENTOLIN TAB 4MG · ATC R03CC02 SALBUTAMOL · form Tablet · route Oral · ingredients SALBUTAMOL SULFATE 4 MG/TAB · company Glaxo canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ventolin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01932691)

Source record
DIN 01932691: Ventolin Raw flags: notABenefit=Y, sec3=Y Item: 121200021; group id 235; item number 0417; lccId None; manufacturer id GLA Source form: Tab; strength: 4mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01932691 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15121
Interchangeable products
Apo-Salvent · DIN 02146851 · $0.2134
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01932691
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 10, 1996 — choose a marketed DIN from the same-category list.

Apo-Salvent · DIN 00790419 · 100 mcg/Metered Dose · inhaler, 200 doses

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.Discontinued April 17, 2025 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Salvent · DIN 00790419 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2025-04-17 · brand APO-SALVENT AEM 100MCG · ATC R03AC02 SALBUTAMOL · form Metered-dose aerosol · route Inhalation · ingredients SALBUTAMOL 100 MCG/ACT · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Salvent: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00790419)

Source record
DIN 00790419: Apo-Salvent Raw flags: notABenefit=Y, sec3=Y Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id APX Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00790419 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9941
Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000 Apo-Salbutamol HFA · DIN 02245669 · $5.0000 Novo-Salmol · DIN 00874086 · not recorded Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded Salbutamol HFA · DIN 02419858 · $5.0000 Teva-Salbutamol HFA · DIN 02326450 · $5.0000 Ventolin · DIN 02213478 · not recorded Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: active shortage (reported March 10, 2017, last updated October 5, 2017) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00790419
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 17, 2025 — choose a marketed DIN from the same-category list.

Novo-Salmol · DIN 00874086 · 100 mcg/Metered Dose · inhaler, 200 doses

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-10 — choose a marketed DIN from the same-category list.Discontinued August 10, 2005 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-08-10 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Novo-Salmol · DIN 00874086 Manufacturer: Novopharm Ltd.; listing date 1996-10-01 Health Canada: Cancelled post market since 2005-08-10 · brand NOVO-SALMOL INHALER 100MCG/AEM · ATC R03CC02 SALBUTAMOL · form Metered-dose aerosol · route Oral · ingredients SALBUTAMOL 100 MCG/ACT · company Novopharm limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Novo-Salmol: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00874086)

Source record
DIN 00874086: Novo-Salmol Raw flags: notABenefit=Y, sec3=Y Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id NOP Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00874086 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11290
Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000 Apo-Salbutamol HFA · DIN 02245669 · $5.0000 Apo-Salvent · DIN 00790419 · not recorded Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded Salbutamol HFA · DIN 02419858 · $5.0000 Teva-Salbutamol HFA · DIN 02326450 · $5.0000 Ventolin · DIN 02213478 · not recorded Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00874086
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 10, 2005 — choose a marketed DIN from the same-category list.

Ratio-Salbutamol Inhaler · DIN 00851841 · 100 mcg/Metered Dose · inhaler, 200 doses

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-07-17 — choose a marketed DIN from the same-category list.Discontinued July 17, 2009 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-07-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-07-17 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ratio-Salbutamol Inhaler · DIN 00851841 Manufacturer: Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2009-07-17 · brand RATIO-SALBUTAMOL · ATC R03AC02 SALBUTAMOL · form Metered-dose aerosol · route Inhalation · ingredients SALBUTAMOL 100 MCG/ACT · company Ratiopharm inc division of teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ratio-Salbutamol Inhaler: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00851841)

Source record
DIN 00851841: Ratio-Salbutamol Inhaler Raw flags: notABenefit=Y, sec3=Y Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id RPH Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00851841 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10209
Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000 Apo-Salbutamol HFA · DIN 02245669 · $5.0000 Apo-Salvent · DIN 00790419 · not recorded Novo-Salmol · DIN 00874086 · not recorded Salbutamol HFA · DIN 02419858 · $5.0000 Teva-Salbutamol HFA · DIN 02326450 · $5.0000 Ventolin · DIN 02213478 · not recorded Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00851841
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 17, 2009 — choose a marketed DIN from the same-category list.

Ventolin · DIN 02213478 · 100 mcg/Metered Dose · inhaler, 200 doses

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-01-22 — choose a marketed DIN from the same-category list.Discontinued January 22, 2003 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-01-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-01-22 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ventolin · DIN 02213478 Manufacturer: Glaxo Wellcome Inc.; listing date 1997-07-12 Health Canada: Cancelled post market since 2003-01-22 · brand VENTOLIN INHALER · ATC R03AC02 SALBUTAMOL · form Metered-dose aerosol · route Inhalation · ingredients SALBUTAMOL 100 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ventolin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02213478)

Source record
DIN 02213478: Ventolin Raw flags: notABenefit=Y, sec3=Y Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id GLW Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02213478 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43105
Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000 Apo-Salbutamol HFA · DIN 02245669 · $5.0000 Apo-Salvent · DIN 00790419 · not recorded Novo-Salmol · DIN 00874086 · not recorded Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded Salbutamol HFA · DIN 02419858 · $5.0000 Teva-Salbutamol HFA · DIN 02326450 · $5.0000 Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02213478
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 22, 2003 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (R03AC, R03C): coverage varies; not interchangeable

  • Terbutaline (Bricanyl Turbuhaler): general benefit
  • Formoterol (Foradil): limited Use 132
  • Formoterol (Oxeze Turbuhaler): limited Use 132
  • Indacaterol (Onbrez Breezhaler): limited Use 443
  • Salmeterol (SereVent Diskus): limited Use 132, 391
  • Orciprenaline (Alupent): general benefit, not a benefit

10 more in the class list below

Ipratropium bromide/salbutamol

2 Limited Use · 1 not a benefit

Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · 500 mcg/2.5 mg/2.5 mL · Inh Sol-2.5mL Amp Pk

Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 256 Patients who have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 257 Patients with cystic fibrosis in whom nebulizer therapy is indicated; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 258 Patients with severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 259 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 Manufacturer: MDA Inc.; listing date 2019-12-20 Health Canada: Marketed since 2026-08-28 · brand IPRATROPIUM BROMIDE AND SALBUTAMOL SULPHATE INHALATION SOLUTION · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Juno pharma canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ipratropium Bromide and Salbutamol Sulph: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8066). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02483394)

Source record
DIN 02483394: Ipratropium Bromide and Salbutamol Sulph Raw flags: sec12=Y, sec3=Y Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id MDI Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8066; ministry $0.8066 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02483394 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97384
Interchangeable products
Combivent UDV · DIN 02231675 · not recorded Teva-Combo Sterinebs · DIN 02272695 · $0.8066
Shortage status: resolved shortage (ended April 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02483394
Shortage record checked October 6, 2026

Teva-Combo Sterinebs · DIN 02272695 · 500 mcg/2.5 mg/2.5 mL · Inh Sol-2.5mL Amp Pk

Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 256 Patients who have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 257 Patients with cystic fibrosis in whom nebulizer therapy is indicated; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 258 Patients with severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 259 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Combo Sterinebs · DIN 02272695 Manufacturer: Teva Canada Limited; listing date 2006-01-24 Health Canada: Marketed since 2012-07-17 · brand TEVA-COMBO STERINEBS · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Combo Sterinebs: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8066). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02272695)

Source record
DIN 02272695: Teva-Combo Sterinebs Raw flags: sec12=Y, sec3=Y Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id TEV Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8066; ministry $0.8066 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02272695 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75820
Interchangeable products
Combivent UDV · DIN 02231675 · not recorded Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · $0.8066
Shortage status: resolved shortage (ended April 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02272695
Shortage record checked October 6, 2026

Combivent UDV · DIN 02231675 · 500 mcg/2.5 mg/2.5 mL · Inh Sol-2.5mL Amp Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.Discontinued January 8, 2020 · checked November 18, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 256 Patients who have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 257 Patients with cystic fibrosis in whom nebulizer therapy is indicated; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 258 Patients with severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 259 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Combivent UDV · DIN 02231675 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 1998-12-31 Health Canada: Cancelled post market since 2020-01-08 · brand COMBIVENT UDV · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Combivent UDV: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02231675)

Source record
DIN 02231675: Combivent UDV Raw flags: notABenefit=Y, sec3=Y Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id BOE Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231675 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51050
Interchangeable products
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · $0.8066 Teva-Combo Sterinebs · DIN 02272695 · $0.8066
Shortage status: discontinued (January 8, 2020, reported by BOEHRINGER INGELHEIM (CANADA) LTD LTEE); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231675
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 8, 2020 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (R03AC, R03C): coverage varies; not interchangeable

  • Terbutaline (Bricanyl Turbuhaler): general benefit
  • Formoterol (Foradil): limited Use 132
  • Formoterol (Oxeze Turbuhaler): limited Use 132
  • Indacaterol (Onbrez Breezhaler): limited Use 443
  • Salmeterol (SereVent Diskus): limited Use 132, 391
  • Orciprenaline (Alupent): general benefit, not a benefit

10 more in the class list below

Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (12:08 Parasympatholytic (Cholinergic Blocking) Agents) and how they are covered

Matched class: 12:08 Parasympatholytic (Cholinergic Blocking) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, BENZTROPINE MESYLATE, ETHOPROPAZINE HCL, GLYCOPYRRONIUM BROMIDE, PROCYCLIDINE HCL, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM Some products covered without a code (check the product listing): IPRATROPIUM BROMIDE, OXYBUTYNIN CHLORIDE, TRIHEXYPHENIDYL HCL 12:08 Parasympatholytic (Cholinergic Blocking) Agents

ACLIDINIUM BROMIDE

· 1 products · General benefit · strengths: 400mcg/actuation · Pd Inh-60 Dose Pk

BENZTROPINE MESYLATE

· 1 products · General benefit · strengths: 1mg · Tab

ETHOPROPAZINE HCL

· 1 products · General benefit · strengths: 50mg · Tab

GLYCOPYRRONIUM BROMIDE

· 1 products · General benefit · strengths: 50mcg · Inh Pd-Cap

IPRATROPIUM BROMIDE

· 12 products · Listed, not a benefit (3), Limited Use, codes 256, 257, 258, 259 (3), Limited Use, codes 265, 266, 267, 268 (4), General benefit (2) · strengths: 250mcg/mL, 125mcg/mL, 20mcg/Metered Dose · Inh Sol-20mL Pk, Inh Sol-2mL UDV Pk, Inh-200 Dose Pk

OXYBUTYNIN CHLORIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1mg/mL, 5mg · O/L, Tab

PROCYCLIDINE HCL

· 1 products · General benefit · strengths: 2.5mg · Tab

TRIHEXYPHENIDYL HCL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 2mg, 5mg · Tab

HYOSCINE BUTYLBROMIDE

· 2 products · Limited Use, codes 481 · strengths: 10mg · Tab

SCOPOLAMINE HYDROBROMIDE

· 4 products · Listed, not a benefit (2), Limited Use, codes 481 (2) · strengths: 0.4mg/mL, 0.6mg/mL · Inj Sol (Preservative Free)

FLAVOXATE HCL

· 2 products · Listed, not a benefit · strengths: 200mg · Tab

TRIMEBUTINE MALEATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:08 and 5 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants

Other drugs in the same formulary class (12:12 Sympathomimetic (Adrenergic) Agents) and how they are covered

Matched class: 12:12 Sympathomimetic (Adrenergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: EPINEPHRINE HCL, TERBUTALINE SULFATE Some products covered without a code (check the product listing): ORCIPRENALINE SULFATE 12:12 Sympathomimetic (Adrenergic) Agents

TERBUTALINE SULFATE

· 2 products · General benefit · strengths: 0.5mg/Dose · Inh-100 Dose Pk, Inh-120 Dose Pk

FORMOTEROL FUMARATE

· 1 products · Limited Use, codes 132 · strengths: 12mcg/Cap · Inh Pd-Device Pk

FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 132 · strengths: 6mcg/Metered Dose, 12mcg/Metered Dose · Pd Inh-60 Dose Pk

INDACATEROL

· 1 products · Limited Use, codes 443 · strengths: 75mcg · Inh Pd-Cap

SALMETEROL XINAFOATE

· 1 products · Limited Use, codes 132, 391 · strengths: 50mcg · Pd Inh-60 Dose Pk

ORCIPRENALINE SULFATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2mg/mL · O/L

ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 459 · strengths: 400mcg & 12mcg · Metered Dose Pd Inh-60 Dose Pk

BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg/6mcg, 200mcg/6mcg · Pd Inh-120 Dose Pk

BUDESONIDE&GLYCOPYRRONIUM (GLYCOPYRRONIUM BROMIDE)&FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 638 · strengths: 160mcg & 7.2mcg & 5mcg/Act · Metered Dose Inh-120 Dose Pk

FLUTICASONE FUROATE & UMECLIDINIUM BROMIDE & VILANTEROL TRIFENATATE

· 1 products · Limited Use, codes 567 · strengths: 100mcg & 62.5mcg & 25mcg · Pd Inh-30 Dose Pk

FLUTICASONE FUROATE & VILANTEROL

· 2 products · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) · strengths: 100mcg & 25mcg, 200mcg & 25mcg · Blister Pd Inh-30 Dose Pk

INDACATEROL & GLYCOPYRRONIUM

· 1 products · Limited Use, codes 459 · strengths: 110mcg & 50mcg · Inh Pd-Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:12 and 4 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-SALBUTAMOL STERINEBSTM P.F. (salbutamol sulphate Solution) is indicated for: • the treatment of severe bronchospasm associated with exacerbations of chronic bronchitis and bronchial asthma. It can be used by “wet” nebulization. When administered through a nebulizer, it should be used with compressed air or oxygen. Pediatrics (< 5 years of age): Experience is insufficient for recommending the treatment of children under 5 years of age. https://pdf.hres.ca/dpd_pm/00084629.PDF PM date: October 28, 2022 Source product: TEVA-SALBUTAMOL STERINEBS P.F.; DIN 01926934; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-COMBO Sterinebs® (salbutamol sulphate and ipratropium bromide) Inhalation Solution in unit dose vials is indicated for the management of bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD) who require regular treatment with both ipratropium and salbutamol. Treatment should be initiated and administered under medical supervision, e.g. in the hospital setting. Home based treatment can be recommended in exceptional cases (severe symptoms or experienced patients requiring higher doses) when a low dose rapid acting beta-agonist bronchodilator has been insufficient in providing relief after consultation with an experienced physician. Administration should be stopped when sufficient symptom relief is achieved. Pediatrics: The efficacy and safety in children and adolescents under 18 years has not been established. TEVA-COMBO Sterinebs® (salbutamol sulphate and ipratropium bromide) Inhalation Solution is not indicated in this patient population. Geriatrics: Page 3 of 48 Elderly patients can use TEVA-COMBO Sterinebs® (s… https://pdf.hres.ca/dpd_pm/00033894.PDF PM date: March 1, 2016 Source product: TEVA-COMBO STERINEBS; DIN 02272695; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Salbutamol HFA · DIN 02245669 Shortage status: active shortage (reported 2026-06-16, last updated 2026-06-18); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245669

Check this DIN again

Airomir HFA · DIN 02232570 Shortage status: discontinued (2023-01-04, reported by BAUSCH HEALTH, CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02232570

Check this DIN again

Apo-Salvent · DIN 02146843 Shortage status: discontinued (2018-07-12, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02146843

Check this DIN again

Apo-Salvent · DIN 02146851 Shortage status: discontinued (2018-07-12, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02146851

Check this DIN again

Ventolin Nebules P.F. · DIN 02213419 Shortage status: discontinued (2022-06-17, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02213419

Check this DIN again

Ventolin Nebules P.F. · DIN 02213427 Shortage status: discontinued (2022-06-29, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02213427

Check this DIN again

Apo-Salvent · DIN 00790419 Shortage status: active shortage (reported 2017-03-10, last updated 2017-10-05) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00790419

Check this DIN again

Combivent UDV · DIN 02231675 Shortage status: discontinued (2020-01-08, reported by BOEHRINGER INGELHEIM (CANADA) LTD LTEE); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231675

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Ventolin, Ventolin Nebules P.F., Apo-Salvent, Novo-Salmol, Ratio-Salbutamol Inhaler, Combivent UDV: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026